Nick Bansback
Nick Bansback
School of Population and Public Health, University of British Columbia
Verified email at ubc.ca
Title
Cited by
Cited by
Year
The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis
D Guh, W Zhang, N Bansback, Z Amarsi, CL Birmingham, A Anis
BMC Public Health 9 (1), 88, 2009
32402009
Obesity and overweight in Canada: an updated cost‐of‐illness study
AH Anis, W Zhang, N Bansback, DP Guh, Z Amarsi, CL Birmingham
Obesity Reviews 11 (1), 31-40, 2010
3142010
Measuring and valuing productivity loss due to poor health: A critical review
W Zhang, N Bansback, AH Anis
Social Science & Medicine, 2010
2522010
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis
EJ Mills, S Kanters, A Hagopian, N Bansback, J Nachega, M Alberton, ...
BMJ 343, 2011
2182011
Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
A Brennan, N Bansback, A Reynolds, P Conway
Rheumatology 43 (1), 62-72, 2004
1982004
Using a discrete choice experiment to estimate health state utility values
N Bansback, J Brazier, A Tsuchiya, A Anis
Journal of Health Economics 31 (1), 306-318, 2012
1732012
Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis
RM Nixon, N Bansback, A Brennan
Statistics in medicine 26 (6), 1237-1254, 2007
1682007
The impact of age-related macular degeneration on health status utility values
M Espallargues, CJ Czoski-Murray, NJ Bansback, J Carlton, GM Lewis, ...
Investigative ophthalmology & visual science 46 (11), 4016-4023, 2005
1642005
Validity of the work productivity and activity impairment questionnaire-general health version in patients with rheumatoid arthritis
W Zhang, N Bansback, A Boonen, A Young, A Singh, AH Anis
Arthritis research & therapy 12 (5), R177, 2010
1492010
Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
NJ Bansback, A Brennan, O Ghatnekar
Annals of the rheumatic diseases 64 (7), 995-1002, 2005
1462005
Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation Studies
N Bansback, A Tsuchiya, J Brazier, A Anis
PLoS ONE 7 (2), e31115, 2012
1452012
A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada
F Xie, E Pullenayegum, K Gaebel, N Bansback, S Bryan, A Ohinmaa, ...
Medical care 54 (1), 98-105, 2016
1442016
Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
A Brennan, N Bansback, R Nixon, J Madan, M Harrison, K Watson, ...
Rheumatology 46 (8), 1345-1354, 2007
1352007
The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons
R Nixon, N Bansback, A Brennan
Rheumatology 46 (7), 1140, 2007
1252007
Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents
A Finckh, N Bansback, CA Marra, AH Anis, K Michaud, S Lubin, M White, ...
Annals of internal medicine 151 (9), 612-621, 2009
1172009
Physician attitudes toward shared decision making: A systematic review
S Pollard, N Bansback, S Bryan
Patient education and counseling 98 (9), 1046-1057, 2015
1152015
Biologic drugs for rheumatoid arthritis in the medicare program: A cost‐effectiveness analysis
AJ Wailoo, N Bansback, A Brennan, K Michaud, RM Nixon, F Wolfe
Arthritis & Rheumatism 58 (4), 939-946, 2008
1122008
Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis
N Bansback, S Sizto, H Sun, S Feldman, MK Willian, A Anis
Dermatology 219 (3), 209-218, 2009
1062009
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
S Kanters, M Vitoria, M Doherty, ME Socias, N Ford, JI Forrest, E Popoff, ...
The Lancet HIV 3 (11), e510-e520, 2016
982016
An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists
NJ Bansback, DA Regier, R Ara, A Brennan, K Shojania, JM Esdaile, ...
Drugs 65 (4), 473-496, 2005
942005
The system can't perform the operation now. Try again later.
Articles 1–20